Abstract. Background: In Côte d'Ivoire, acute leukemias account for 12.5% of hematological malignancies. Acute leukemias are due to an anomaly of the stem cell characterized among other things by the expression of CD34 + CD38 -surface markers. This CD34 + CD38 -phenotype as well as other factors such as tumor syndrome, high leukocytosis and blasts are considered as important factors of poor prognosis. We therefore proposed to investigate the prognostic value of the expression of CD34 + CD38 -markers in acute leukemias in Abidjan. Methods: We selected 23 patients aged 33 years on whom we performed Complete Blood Count, bone marrow aspiration and immunophenotyping. To search for myeloperoxydase, smears of blood or bone marrow were stained with benzidine and revealed by the use of Hydrogen peroxide. Acute leukemias were then identified and distributed using the score proposed by the European Group for the Immunological characterization of Leukemias. The definitive diagnosis was made by combining morphological characters that serve as the basis for the French-American-British classification as well as cytochemical and immunophenotypic characters. Results: According to the cytological and immunophenotypic classifications, the acute lymphoid leukemia 2 and B IV predominated. 52.2% (12/ Introduction. In Côte d'Ivoire, cancers in general and hematological malignancies in particular are booming due to urbanization and HIV-AIDS. [1] [2] [3] According to Tanon, 3 non-Hodgkin lymphomas were associated with HIV infection but not with leukemia. 3 Acute leukemia (AL) accounted for 12.5% of hematological malignancies and were more related with pollution and environment. 1, 2 Factors such as tumor syndrome, high leukocytosis and blasts are considered as factors of poor prognosis. However they are not the only ones. Indeed Basso 4 and George 5 pointed out that AL is a stem cell disease in which the stem cell self-renewal mechanisms are preserved but the tight growth control is lost due to malignant transformation. Leukemia stem cells are thought to reside within the CD34 + CD38 -population.
5-
10 CD34 has been frequently associated with a worse prognosis and a poor outcome in AL. Indeed the expression of P 170 glycoprotein on leukemic cells confers them resistance to chemotherapy or «Multiple Drug Resistance (MDR)». The expression of MDR is related to CD34 phenotype. 4, 9, 10 Conventional chemotherapy, based treatment of leukemia and cancer in general, is primarily directed against the bulk of malignant cells and thus does not eliminate the abnormal stem cells. Those cells are the origin of cancer recurrence and are responsible for relapse. [4] [5] [6] [7] [8] [9] [10] The purpose of this study was to investigate the prognostic value of CD34 + CD38 -expression on leukemic blasts cells in patients with AL in Abidjan. After performing a windowing on blast cells with the CD45 antigen, CD45-blasts were analyzed by kits CD38/CD56/CD19 and CD103/CD22/CD20 or CD45/CD3/CD4 to determine the proliferation lineage. Antigen was considered positive when the expression reached at least 30%. 12, 13 AL were then identified and distributed using the score proposed by the European Group for the Immunological characterization of Leukemia (EGIL). 12, 13 The definitive diagnosis was made by combining morphological characters that serve as the basis for the French-American-British classification (FAB) as well as cytochemical and immunophenotypic characters.
Material and methods.
In acute bi-phenotypic leukemia (Tor B or B/T myeloid) blasts carried both antigens of B and T lineage and antigens of myeloid and lymphoid lineages.
Acute bi-clonal leukemia was characterized by the presence of two morphologically different blastic populations with expression of different antigens. A blastic population should be either positive to benzidine (Mpo + ) and carry T or B lineage antigens. AL undifferentiated was characterized only by cells carriers of immaturity antigens (HLA-DR, CD34 CD38). Unspecified AL cells lacked specific lineage antigens. [11] [12] [13] Immunophenotyping helped to identify patients' CD34 + CD38
-. Patients received induction chemotherapy with a combination of cytarabine and daunorubicine in acute myeloid leukemia (AML). In acute lymphoid leukemia (ALL) the treatment included the administration of steroid, vincristine, daunorubicine, asparaginase and methotrexate. Both are considered gold standard in induction therapy. 1 and 2) .
Results
Immunophenotyping also revealed the presence of Koffi. 14 He worked on the results of the induction treatment in AL, in Abidjan. His patients were 28 years old (range 3 to 54).
Patients were HIV negative. Indeed, Tanon   3 highlighted that cancer was a growing co-morbidity among HIV-infected patients in Côte d'Ivoire and Benin in 2012. With the scale-up of antiretroviral therapy in developing countries, cancer will contribute more and more to the HIV/AIDS disease burden. According to Tanon, 3 Kaposi sarcoma, non-Hodgkin lymphoma, cervical cancer, anogenital cancer and liver cancer were all associated with HIV infection but not with leukemia.
The late presentation of patients to the hospital and the poor access to care explained the importance of the tumor mass that resulted in significant leukocytosis and medullar blasts with respective values of 56.7 ± 74.2 G/l and 79.4 ± 20.7% and thrombopenia (table 1) .
Unlike Koffi 14 and Braham Jmili, 15 who had described in their series a predominance of ALL 1 , we found that ALL 2 were in majority (table 1). We did not diagnose any erythrocytic leukemia or megakaryocytic leukemia. They are uncommon in the African series 1, 11, 14, 15 ( (table 3) . The high cost of drugs, the low income, the lack of insurance and social security for population represented a serious difficulty for the treatment of the patients. This situation was also described by Ly. (table 3) . This result, at first sight, was not in agreement with Koffi 14 who found 60% of complete remission in AL. However, a little deeper study allows realizing that many patients were excluded in this study. Indeed, only 45 patients were enrolled over a period of 5 years while in one year we recruited 23 patients in the same hospital albeit at different times. Improved diagnostic techniques may have also led to obtain a larger sample.
Ebinger, 6 Vergez, 8 Witte 9 suggested that in ALL and in AML, the proportion of CD34 + CD38 -at the diagnosis may serve as a prognosis marker as well. A higher proportion of CD34 + CD38 -correlated with unfavorable prognosis. In our study, the expression of CD34 + CD38 -in blasts seemed to have no influence on the results of the induction treatment. And we could not come to the same conclusion particularly for 2 reasons. On the one hand, the majority of the patients died very early after the induction therapy. On the other hand, we did not notify the proportion of CD34 + CD38 -cell of each patient. We just identified the CD34 + CD38 -blasts population. A part from CD34 + CD38 -phenotype, there were other important factors for prognosis and treatment such as cytogenetic and molecular anomalies. Vergez 8 in AML, found that a proportion of CD34 + CD38
-/low CD123 + cells was greater than 15% at the diagnosis and unfavorable karyotype were significantly correlated with the lack of complete response. Chauchan 16 investigated the expression of MDR1 and apoptotic (p53) genes in AL. MDR 1 expression was significantly associated with the expression of immature stem cell marker CD 34.
The leukemia initiating cells was found within the CD34 + CD38 -cell compartment. These more immature cells were more resistant to therapy. [6] [7] [8] [9] [10] Resistance to chemotherapy is a major impediment to the successful treatment in AL. The expression of genes involved in drug resistance and apoptosis could be responsible for this. Multidrug transporter genes such as MDR1 lead to a rapid clearance of cytotoxic drugs. [7] [8] [9] [10] 15 As we did not perform cytogenetic and molecular studies we could not link up the results of the induction treatment and the presence or the absence of leukemic stem cell CD34 + CD38 -population with the MDR genes expression ( 
